Take a fresh look at the evidence on specific and relevant topics related to cardiovascular disease. Review the following learning resources to grasp topics, including:

• Sympathetic nervous system over activity as a pathogenetic mechanism in hypertensive-related cardiovascular risk and discuss if  this  parameter  can  be  considered  a  target  in  antihypertensive treatment
• The  role  of  fixed  dose  combinations  in  the  treatment  of hypertension and address the therapeutic relevance of the new fixed dose combination beta-blocker/calcium antagonist
• Best  practice  according  to  guidelines  for  treating hypertensive patients with coronary artery disease
• Complex transition from hypertension to heart failure and  discuss  the  possible  beneficial  effect  of  pharmacological treatment
• The best beta-blocker compound when treating patients with diabetes

Sympathetic nervous system and cardiovascular risk

                            G. Mancia (Italy)

Should increased heart rate be considered a target in cardiovascular treatment?

                            H. A.J. Struijker-Boudier (The Netherlands)

New possibilities for the fixed-dose combination treatment in hypertension

                            S. Taddei (Italy)

Best practice in the management of stable chronic angina

                            B. Tomlinson (Hong Kong)    

From hypertension to heart failure: prevention strategies

                            E. Erdmann (Germany)

Use of betablockers in diabetes

                            G. Grassi (Italy)

The role of beta-blockers in hypertensive patients

                             H. A.J. Struijker-Boudier (The Netherlands)

How to optimize treatment in patients with heart failure

                             E. Erdmann (Germany)